
Myeloproliferative neoplasms (MPNs) are rare blood cancers that alter how the body produces blood cells, requiring individualized care. In this episode, Catriona Jamieson, MD, PhD, of the University of California San Diego, shares the latest breakthroughs in MPN research, from detecting disease progression earlier to developing targeted, personalized therapies.
We explore MPN subtypes, the role of genetic testing, and current and emerging therapies. Whether you are navigating polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF), this conversation offers practical insights into today’s care landscape and new reasons for hope.
Podcast: Play in new window | Download
Subscribe: Spotify | Pandora | Podchaser | More
CLICK HERE to participate in our episode survey.Mentioned on this episode:
- Myeloproliferative neoplasms (MPN)
- Acute myeloid leukemia (AML)
- MPN Research Foundation
- MPN Research Foundation and Blood Cancer United Exclusive Clinical Trial Navigation
- Dynamic Internation Prognostic Scoring System (DIPSS/DIPPS Plus)
- MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form)
- Mutation-Enhanced International Prognostic Scoring System
- World Health Organization (WHO) MPN Classification
- Clinical Trial Support Center
Additional Blood Cancer United Support Resources:
- Information Specialists
- Free Nutrition Consultations
- Free telephone/web patient programs
- SHARE web series
- Online videos
- Free booklets
- Young Adult Resources
- Young Adult Online Chat
- Caregiver support
- Caregiver Workbook
- Caregiver Chat
- Support groups
- Patient Community
- Medical Debt Case Management Program
- Financial support
- Survivorship Workbook
- Advocacy and Public Policy
- Mental Health Resources
Episode supported by Novartis Pharmaceuticals Corporation; PharmaEssentia USA Corporation; and Takeda Oncology.